Veeva Systems: Near-Term Challenges But Good Prospects Long Term
Positive results amid near-term challenges. Long-term dominance in a growing industry and continued growth from inorganic and organic strategies. Fortress balance sheet.
U.S. Healthtech Industry Analysis
UpdatedMay 28, 2022
DataAggregated Company Financials
Companies77
- 7D5.5%
- 3M-22.0%
- 1Y-39.6%
- YTD-36.4%
In the last week, the Healthtech industry is up 5.5%, with Veeva Systems leading the way, up 4.6%. In the same time, Biotricity was down 17%. In the past year, the industry is down 40%. As for the next few years, earnings are expected to grow by 34% per annum.
Industry Valuation and Performance
Has the U.S. Healthtech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE |
|---|---|---|---|---|
| Sat, 28 May 2022 | US$116.6b | US$23.2b | -US$7,359,237,621.00 | 49x |
| Mon, 25 Apr 2022 | US$131.2b | US$23.8b | -US$823,593,303.00 | 65.7x |
| Wed, 23 Mar 2022 | US$141.8b | US$23.9b | -US$869,737,328.00 | 83x |
| Fri, 18 Feb 2022 | US$152.4b | US$23.9b | -US$1,703,521,715.00 | 90.3x |
| Sun, 16 Jan 2022 | US$156.4b | US$23.7b | -US$1,729,195,532.00 | 92.6x |
| Tue, 14 Dec 2021 | US$168.9b | US$23.1b | -US$1,291,880,240.00 | 97.6x |
| Thu, 11 Nov 2021 | US$203.0b | US$22.9b | -US$1,341,755,766.00 | 113x |
| Sat, 09 Oct 2021 | US$188.8b | US$22.1b | -US$1,254,921,150.00 | 105.8x |
| Mon, 06 Sep 2021 | US$197.2b | US$21.9b | -US$1,313,886,449.04 | 92.8x |
| Wed, 04 Aug 2021 | US$188.7b | US$21.9b | -US$1,229,889,348.31 | 94.4x |
| Sat, 08 May 2021 | US$170.8b | US$20.3b | -US$1,351,563,571.31 | 93.6x |
| Tue, 09 Feb 2021 | US$188.6b | US$19.1b | -US$2,269,608,711.31 | 81.3x |
| Mon, 02 Nov 2020 | US$150.5b | US$17.5b | -US$1,422,222,372.31 | 92.6x |
| Thu, 06 Aug 2020 | US$110.7b | US$14.9b | -US$1,221,765,849.31 | 42.7x |
| Sun, 10 May 2020 | US$86.3b | US$14.2b | -US$1,262,876,112.31 | 44.3x |
| Sat, 01 Feb 2020 | US$73.5b | US$13.6b | -US$316,037,126.31 | 55.6x |
| Tue, 05 Nov 2019 | US$67.9b | US$13.4b | -US$263,823,532.31 | 48.5x |
| Fri, 09 Aug 2019 | US$74.5b | US$13.1b | -US$85,430,019.31 | 50x |
Median PE Ratio
49.3x
Current Industry PE
- Investors are more pessimistic on the industry, indicating that they anticipate long-term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 49.0x which is lower than its 3-year average PE of 71.2x.
Past Earnings Growth
- Total earnings for the Health Care Technology industry have declined over the last three years, with the industry now making a loss overall.
- Meanwhile revenues have grown 23% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Comparison
How does U.S. Healthtech compare with similar industries?
| US Market | 5.92% | |
| Healthcare | 1.80% | |
| Healthtech | 5.47% | |
| Healthtech | 5.47% | |
Industry PEThere is insufficient data on the sub-industries of this industry.
Forecasted GrowthThere is insufficient data on the sub-industries of this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| VEEV Veeva Systems | US$172.00 | 4.6% +US$1.2b | -41.0% | PS62.3x | |
| NUTX Nutex Health | US$10.00 | 21.2% +US$1.1b | n/a | PS40.9x | |
| DOCS Doximity | US$35.39 | 12.1% +US$732.7m | n/a | PS50.8x | |
| TDOC Teladoc Health | US$35.77 | 9.3% +US$488.4m | -76.2% | PS2.7x | |
| MPLN MultiPlan | US$5.38 | 13.3% +US$402.6m | -36.3% | PS34.3x |
